Want to know what's happening next in healthcare?

MedCityNews is the leading online news source for the business of innovation in healthcare.


“MedCity news is a peerless national resource for those of us who really want to stay on top the very latest news in healthcare from incumbents to startups. ”

Elliot Menschik, DreamIt Ventures partner; Venturef0rth founder; Penn professor


Sign up for our daily newsletter


LabCorp gets FTC OK for $85M Orchid acquisition

December 8, 2011 3:05 pm by | 0 Comments

LabCorp (NYSE:LH) finally has the regulatory go-ahead to complete its $85 million acquisition of DNA testing company Orchid Cellmark (NASDAQ:ORCH).

The laboratory services and diagnostics firm said that it has reached an agreement with the U.S. Federal Trade Commission that calls for the company to sell off parts of Orchid’s U.S. government paternity business following the closing of the deal. LabCorp said it will sell those assets to DNA Diagnostics Center, a Fairfield, Ohio-based company that provides DNA paternity testing at its locations throughout the country and around the world.

The agreement with the FTC comes eight months after Burlington, North Carolina-based LabCorp announced it would acquire Orchid. The deal was intended to bolster LabCorp’s identity testing offerings while also giving the company a presence in the United Kingdom market, where Princeton, New Jersey-based Orchid already has operations.

Advertisement

LabCorp initially expected the Orchid deal to close in May. But in the following months, the FTC kept asking for more information. LabCorp has extended its offer for Orchid 10 times while regulators continued their review of the deal.

LabCorp’s cash tender offer of $2.80 per share is now set to expire at 5 p.m. on Dec. 9.

 

Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

By Frank Vinluan

Frank Vinluan is the North Carolina Bureau Chief for MedCity News.
More posts by Author

0 comments